Leflunomide Medac (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for de novo synthesis of pyrimidine nucleotides. By limiting pyrimidine production, the drug reduces the proliferation of activated T‑lymphocytes, thereby dampening the inflammatory processes that cause joint damage in arthritis.

The dosage of Leflunomide Medac is determined by the prescribing physician based on the individual’s clinical condition, disease severity, and laboratory monitoring. Physicians typically start with a loading dose followed by a maintenance dose, but exact amounts should only be set by a qualified healthcare professional.

Leflunomide is classified as having unknown safety in pregnancy and is considered teratogenic. Women of child‑bearing potential must use effective contraception during treatment and for a defined wash‑out period after discontinuation. Breastfeeding is not recommended while taking leflunomide because of potential infant exposure.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and necessary import documentation.

Leflunomide is an oral synthetic DMARD, whereas the most common alternative, methotrexate, is also oral but works through folate antagonism. Biologic agents such as TNF‑α inhibitors target specific cytokines and are administered by injection. Leflunomide offers a convenient oral option with a distinct mechanism, but its safety profile—particularly liver and hematologic risks—differs from both methotrexate and biologics.

Leflunomide Medac tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Leflunomide Medac is taken orally, usually with a full glass of water. The tablets can be swallowed with or without food, but consistent administration with respect to meals helps maintain stable drug levels. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious adverse events include severe liver injury, aplastic anemia, and life‑threatening infections. Patients should be educated to report symptoms such as persistent jaundice, unexplained fatigue, easy bruising, or signs of infection promptly, and regular laboratory monitoring is essential to detect early toxicity.

Leflunomide is contraindicated in patients with severe hepatic impairment, active serious infections, and in women who are pregnant or planning pregnancy without effective contraception. It should also be avoided in individuals with known hypersensitivity to leflunomide or its excipients.